Executive Decisions Roundup
This article was originally published in The Tan Sheet
Executive Summary
Another Coca-Cola exec pops up at NBTY; Hussain helms Glaxo pharma globally; China TCM office veteran returns; T-Bird tabs Huang as COO; and Lee named Calif. DTSC director.
You may also be interested in...
Carlyle Group Gives NBTY Helm To Former Coca-Cola Executive Cahillane
Steven Cahillane, who left his post as president of Coca-Cola Co.’s Americas division in 2013, is moving to NBTY to replace Jeffrey Nagel after the supplement manufacturer and retailer reported flat sales for its most recent earnings period and after net income dropped nearly 12% during the firm’s previous fiscal year.
US FDA Supplement Facility Inspection Numbers Back To Typical Along With GMP Problems Found
Supplement facility GMP inspections by FDA in 2022 along with the frequency of form 483s sent to firms following inspections return to roughly pre-pandemic annual numbers after dipping during 2020 and 2021.
US OTC Monograph Drug Facility Fees Up 8%, Higher Price Tags Stuck On OMORs, Too
FY2023 OTC monograph user fee target facility fee revenue is $25.4m from manufacturers’ fees of $26,153 and contract manufacturers’ fees of $17,435, all due by 1 June. OMOR fees are $517,381 for Tier 1 requests and $103,476 for Tier 2.